Alere doubles commitment to aid OAFLA in eliminating mother-to-kid transmission of HIV and EID Alere , a worldwide leader in rapid diagnostics, today doubled its dedication to the Organisation of African First Girls Against HIV/Helps in its efforts to lessen the impact of HIV/AIDS in Africa through the elimination of mother-to-child transmission of HIV and increasing early baby diagnosis http://www.tadalisx.com . Since September 2014, Alere has donated 200,000 HIV/Syphilis Duo rapid tests to aid OAFLA's efforts to lessen mother-to-child transmitting of syphilis and HIV. Today, at a high-level event convened by OAFLA during the 70th UN General Assembly, Alere a lot more than doubled its initial commitment to assist OAFLA and their companions reach yet another 500,000 women that are pregnant, infants, adolescents and additional at-risk populations in Africa with screening and avoidance services.
Preliminary data from the trials are expected to be presented close to the end of 2010. The Company expects to begin a trial in pediatric aHUS patients in the fall of 2010. Additional early clinical encounter with Soliris as a treatment for patients with aHUS was recently presented at the Second International Conference on HUS-MPGN-PNH kept in Innsbruck, Austria and summarized in an announcement by the Company on June 15, 2010. Transplant: Acute Humoral Rejection Soliris is being investigated as cure for patients going through kidney transplant who are at elevated risk of antibody mediated rejection, also called acute humoral rejection, or AHR. The Company is supporting investigator-initiated research in elevated-risk kidney transplantation in the U.S.